3 hrs ago | Reuters
GSK melanoma drugs may steal market from Roche
Two experimental skin cancer drugs from GlaxoSmithKline - each designed to block different pathways used by tumour cells - look set to steal a march on Roche's pioneering melanoma treatment Zelboraf, according to Citigroup.
9 hrs ago | Nottingham Evening Post
3. Indian pharma giant eyes Nottingham
The city is the home of healthcare retailer Boots and has strong pharmacy and chemistry departments at the University of Nottingham which recently announced that GlaxoSmithKline was giving 12m for new sustainable chemistry laboratories.
GlaxoSmithKline Diabetes Drug Data Revealed Amid Hostile Takeover
GlaxoSmithKline Plc will reveal detailed results today on an experimental treatment for diabetes that's part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc.
Stock Insights: Costco Wholesale, Human Genome, NewLink Genetics, VeriFone,General Mills May 25th
Costco Wholesale Corporation : Baird raised its price target on Costco following Q3 results.
Local News: GSK workers give charity's barge a lick of paint
It was a case of all hands on deck for the 20 GlaxoSmithKline employees when they repainted Cathja in Isleworth.
Collaboration proves to be path to acquisitions by GSK
GlaxoSmithKline may find its next acquisition target where the U.K. drugmaker found the last two: among more than a dozen companies it collaborates with to develop new treatments.
GlaxoSmithKline Amends Offer to Address Human Genome Sciences, Inc. Poison Pill
HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia GlaxoSmithKline plc Wednesday, May 23, tweaked the terms of its hostile $2.59 billion offer for Human Genome Sciences Inc.
EU Big Pharmas Such as AstraZeneca PLC, GlaxoSmithKline, Sanofi...
Drug Giants Such as AstraZeneca PLC , GlaxoSmithKline , Sanofi Join Forces With Academia on $285 Million Antibiotic Pact GlaxoSmithKline and AstraZeneca welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies working alongside public partners to tackle the rising threat ... (more)
GlaxoSmithKline Sifts Through Collaborations for Acquisitions
GlaxoSmithKline Plc may find its next acquisition target where the U.K. drugmaker found the last two: among more than a dozen companies it collaborates with to develop new treatments.
Milestone Triggered in Connection With Filing of New Drug Application in Japan for Arzerra
COPENHAGEN, Denmark, May 24, 2012 -- Genmab A/S announced today a milestone payment of DKK 20 million from GlaxoSmithKline to Genmab in connection with the filing of the New Drug Application to the Japanese Ministry of Health, Labor and Welfare .
Healthcare Business Recap: GlaxoSmithKline Shakes on Human Genome,...
GlaxoSmithKline shares move lower Wednesday as the firm modifies the terms of its $2.6 billion tender offer for Human Genome , which require that its quarry redeem or invalidate its poison pill.
GlaxoSmithKline: The Good News Just Keeps On Coming
Just last month GlaxoSmithKline was in the news for a move to acquire Human Genome Sciences , its partner of up to twenty years for $2.6 billion.
Auxilium, GSK enter sales deal for testosterone gel
But the numbers for companies making the product for men are clear and direct, which is why Auxilium Pharmaceuticals Inc., of Malvern, Pa., and GlaxoSmithKline announced a deal Monday to try to sell more of Testim, Auxilium's prescription form of the gel.
Human Genome Sciences Rejects GlaxoSmithKline's $2.6 Billion Offer
Following GlaxoSmithKline's unsolicited $2.6-billion offer earlier this month for acquiring the biopharmaceutical company Human Genome Sciences , HGS announced late last week that its board of directors had unanimously determined that the offer of $13.00 per share undervalued HGS and issued a shareholder's rights plan advising stockholders to ... (more)
A 'Least-Bad' Option For Foreign Developed Equity Exposure
While we usually recommend using single-country funds as satellite holdings given their niche exposure, we think iShares MSCI United Kingdom Index is suitable as a core foreign-equity holding.
Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
MALVERN, Pa., May 21, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. is raising its full year 2012 revenue guidance to a range of $293 to $315 million and is reducing its guidance for net loss to a range of $5 to $10 million.
GlaxoSmithKline to help sell Auxilium's testosterone gel
Auxilium Pharmaceuticals, Inc. and GlaxoSmithKline entered into an agreement Monday to co-promote Testim, Auxilium's testosterone replacement therapy product used in adult males.
Liberty Media Could Be A Sirius Problem
An interesting scenario is developing in the world of Sirius . For a while now, Liberty Media has been trying to gain control of Sirius XM.
GSK-owned Stiefel Labs loses $1.5M verdict in stock value suit
Stiefel Laboratories has lost a $1.5 million jury verdict to a former employee who claimed the company bought back his stock at artificially low prices before its acquisition in 2009 by GlaxoSmithKline Timothy Finnerty won the judgment on May 16 in federal court in Miami against Stiefel and its former chief executive officer, Charles Stiefel.
Many Rare Mutations May Underpin Diseases
Fifth Estate: Facebook's IPO, free education online, and the 'Obama Dashboard' In the Pipeline: Lobbying dollars in Harrisburg and an upcoming shale author event Science Fair has international flavor Renovations continue on Point State Park fountain New outdoor classroom opens at Children's Museum The task of finding the genetic roots of common ... (more)